INTRODUCTION

Cytosolic
' malic' enzyme [ME; L-malate-NADP+ oxidoreductase (decarboxylating) EC. 1.1. 1 .40] catalyses the NADP+-dependent oxidative decarboxylation of malate to pyruvate and CO2 and further generates NADPH from NADP+. ME has long been believed to be the major generator of NADPH for lipogenesis (reviewed in [1] ). A number of studies have shown that ME gene expression can be modulated at the transcriptional level by the action of the thyroid hormone triiodothyronine [2] [3] [4] [5] [6] and at the post-transcriptional level in response to carbohydrate-or fat-related dietary conditions [2, 3, 7, 8] .
The expression of ME during development has been widely studied by either direct assay of enzyme activity or immunoreactivity of the protein as a function of developmental status [9] [10] [11] . The results obtained from monitoring steady-state levels of rat liver ME mRNA, both during development and in response to hormonal or dietary changes at the suckling/weaning transition, suggest that the changes in rat hepatic ME expression during development are controlled before translation and that diet and hormones are likely to influence expression of ME during development [11, 12] .
Previous studies have demonstrated the ability of the rat ME gene promoter to direct transcription in HeLa cells and in a wide variety of other tissues. It is therefore likely that those factors necessary for transcription of this gene are present not only in HeLa-cell extracts, but in other tissues also. Characterization of both the rat ME gene and the gene promoter region has been reported [13, 14] . The latter was found to resemble the promoter regions of housekeeping genes in that no TATA or CCAAT box motifs could be identified. The rat ME gene promoter has an 83 % GC content and contains nine consensus binding sites for Spl (5'-CCGCCC-3') distributed widely through the core promoter, intron and untranslated regions. The promoter also contains a tandem perfect repeat of 10 bp, known as the direct non-specific nor Spl-consensus-site-containing oligonucleotides can displace those complexes formed between DRP-1 and the DRE sequence, thus confirming sequence-specific binding by this protein. SDS/PAGE analysis of DRE-protein complexes isolated by direct excision and transplantation from retardation gels confirms the presence of the 95 kDa protein and, in addition, suggests that more than one binding site exists for this protein within the DRE. This is in accord with the repeated nature of the DRE DNA sequence which contains two CACC box motifs.
repeat element (DRE). Each 10 bp repeat contains a nonconsensus SpI-binding site, CCACCC, which houses the CACC box. The importance of the CACC box as a transcriptional control element has been demonstrated [5, [15] [16] [17] [18] . Deletion of this region in the rat ME gene promoter shows that it is vital for efficient transcription; its removal lowers transcriptional efficiency to 17% of maximal promoter activity in an in vitro transcription assay [5] . Recent evidence suggests that the general transcription factor Spl differentially interacts with CACC boxes on a number of promoters. For example, Spl has been shown to bind the CACC boxes of the e-, ,-and y-globin promoters, although surprisingly not all of these lie within recognized nonconsensus Spl-binding sites [19] . Detailed analysis of SpI binding to consensus and non-consensus sites reveals that binding to 5'-CCACCC-3' is only 6-fold weaker than binding to the consensus sequence [20] , suggesting that Spl may play a role in vivo in binding to these sequences.
We now report the discovery of a factor present in HeLa-cell nuclear extract, the direct-repeat-binding protein 1 (DRP-1), which binds to the DRE CACC-box-containing sequence in vitro in a sequence-specific manner.
MATERIALS AND METHODS Oligonucleotides
All oligonucleotides used in this study were [21] through Sephadex G-25 superfine resin (Pharmacia). Oligonucleotide sequences used in this study are given below. Spl and DRE oligonucleotides are derived from regulatory regions of the ME gene promoter. Oligonucleotides were: non-specific, 5'-AGCATTCCGGAA-TGCT-3'; Spl, 5'-GGCCGCCGCCCGCCGC-3'; DRE, 5'-GCCTCGCCACCCCCTCTCGCCACCCAC-3'. They were annealed with their complementary sequences (self-annealed for the non-specific oligonucleotide) in equimolar amounts, by heating to 90°C for 5 min then cooling to room temperature at the rate of I°C/min.
Gel-retardation analysis
Typically gel-retardation assay reactions contained 1 ng of endlabelled oligonucleotide, 1 ,ug of poly(dI-dC) (Pharmacia) and 0.5 ,ug of protein in a buffer comprising 25 mM Hepes, pH 7.6, and 1 mM EDTA in a final reaction volume of 40 ,l. Samples were incubated on ice for 30 min, then subjected to electrophoresis on 4 % (19: 1) polyacrylamide gels in 0.5 x TBE (1 M Tris, 0.8 M boric acid, 25 mM EDTA) at 100 V for 2-3 h in 0.5 x TBE electrophoresis buffer. After electrophoresis, the gel was transferred to Whatman 3MM filter paper, dried under vacuum and subjected to autoradiography overnight at -70°C with intensifying screens.
Western-blot analysis Western blotting was carried out essentially as previously described [22] . SpI polyclonal antiserum was a gift from S. Jackson and A. Bannister (Wellcome/CRC Institute, Cambridge, U.K.) and was used in conjunction with the ECL detection system (Amersham) according to the manufacturer's instructions.
Protein purification
HeLa-cell extract (1 ml), prepared as described elsewhere [23] , was applied to a 5 ml Affigel-heparin cartridge (Bio-Rad) preequilibrated with 5 column vol. of buffer A (1O mM Hepes, pH 7.9, 1 mM EDTA). Fractions were collected over a gradient of 0-1 M NaCl in buffer A and adjusted to 10 % glycerol before storage. They were assayed both for their ability to specifically retard DRE probe and by SDS/PAGE analysis. Active fractions were dialysed at 4°C overnight against 2000 vol. of buffer B (1O mM Hepes, pH 7.9, 1 mM EDTA, 10% glycerol, 1 mM dithiothreitol and 1 mM PMSF). These dialysed fractions (1 ml volumes) were loaded on to a Mono Q HR5/5 anion-exchange column (Pharmacia), pre-equilibrated with buffer A. Fractions were eluted in 1 ml volumes over a linear gradient of 0-1 M NaCl in buffer A. Samples were assayed as detailed above. Active fractions were pooled, dialysed against buffer B and, when required, concentrated by reverse dialysis against solid poly-(ethylene glycol) (15) (16) (17) (18) (19) (20) In an effort to characterize proteins that might bind the DRE sequence, crude HeLa-cell extract was fractionated on a heparin-Sepharose column as described in the Materials and methods section. The fractionation profile is shown in Figure  l(a) . The ability of each fraction to retard the DRE oligonucleotide was examined and the results shown in Figure  1(b) . A strong retardation signal is seen for fractions 24-27 (lanes [5] [6] [7] [8] . . . . . . . . . . . . . . . . . . . . . . B . E . Ẽ . . . . . . . . . . . . . . . Figure 1c ). There was no evidence of Spl being present in fractions 24-27 (lanes 1-4). An additional signal, seen in all fractions examined, results from non-specific interaction and is indicated in Figure 1(c) . Those Figure 3 . Gel-retardation analysis of DRP-1 bound to the DRE in the presence of non-specific (lanes 1-3) or S-pl-site-containing (lanes 4-6) competitor oligonucleotides is show%n in Figure 3 Involvement of DRP-1 in formation of complex A and B In order to clarify the role of DRP-l in the formation of the multiple complexes seen in retardation assays, a scaled-up retardation experiment using 250ju1 of purified protein (I jug) and 100 ng of DRE oligonucleotide was performed (results not shown). Retarded complexes (corresponding to bands A, B and C in Figure 3) were excised from the gel and subjected to SDS/PAGE, followed by silver staining. The results are shown in Figure 4 . Complexes A and B, which are the most sensitive to specific competition by the DRE oligonucleotide, both contain Figure 3 Figure 2 . The inability of Spl-site-containing oligonucleotides to compete effectively against DRP-1-DRE complex-formation in retardation experiments (compared with DRE competitor oligonucleotides) confirms that Spl and DRP-1 are distinct proteins.
Incubation of DRE probe with partially purified DRP-1, derived from a single heparin-Sepharose chromatographic step, gives rise to a single retarded species in gel-retardation assays, identical in mobility with that obtained using crude extract (Figure 1) , and reflects the presence of additional DNA-binding proteins in this partially purified sample. Retardation patterns obtained when a more purified DRP-1-containing sample is complexed with DRE probe reveal three distinct retarded complexes designated A, B and C in Figure 3 . Analysis of the protein content of complexes A, B and C by SDS/PAGE of gel slices containing the retarded complexes reveals that the 95 kDa DRP-1 species is present in complexes A and B, but not in C. This suggests that complex A, the complex of least mobility, contains more than one DRP-1 protein bound to the DRE probe. This concept is in line with the repeat nature of the DRE sequence, which offers the opportunity for two DNA-binding events in tandem. Footprinting studies on the ME gene promoter using rat liver nuclear extracts show that both copies of the repeat sequence in the DRE are bound by protein, separated by a dominant DNase I-hypersensitive site corresponding to the 3 bp region that separates the direct repeat sequences [5] . The presence of complex A in gel-retardation experiments may thus be indicative of both target sites being accessible to the protein, i.e. internally located, not situated at the extreme ends of the sequence. Whether the CACC boxes fulfil this positional requirement in the DRE oligonucleotide is not readily apparent. The identification of the CACC box as a major transcriptional element does, however, suggest itself as a candidate for binding. The identity of the protein(s) responsible for complex C formation is at this time unknown. The inability to detect any protein may result from its migration off the end of the gel (< 15-20 kDa), a natural low abundance or imprecise excision of the retarded complex from the retardation gel. The relatively high electrophoretic mobility of the retarded complex would suggest that the protein is of low molecular mass however. The identity of this protein is currently under investigation.
The inability of non-specific or Spl-site-containing DNA duplexes to abolish DRE complex-formation with purified DRP-1 confirms the sequence specificity of DRP-1. The precise role of this protein and the DRE sequence motif in the transcriptional regulation of the ME gene has yet to be determined. In vitro transcription experiments are currently under way which should help to define the effect of Spl and/or DRP-1 binding to the DRE on gene transcription.
